Completed PHASE1 INTERVENTIONAL 2-arm NCT02611921

Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder

Intranasal Ketamine Use in Autism Spectrum Disorder: A Placebo-Controlled Crossover Pilot Study

Sponsor: Children's Hospital Medical Center, Cincinnati

Updated 7 times since 2017 Last updated: Oct 10, 2018 Started: Dec 22, 2015 Primary completion: May 7, 2018 Completion: May 7, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Autism Spectrum Disorder, this trial is completed. The trial is conducted by Children's Hospital Medical Center, Cincinnati and has accumulated 7 data snapshots since 2015. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Jun 2018 — Nov 2018 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Hospital Medical Center, Cincinnati
Cures Within Reach
Roivant Sciences, Inc.

Data source: Children's Hospital Medical Center, Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States